Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Aksjekursen Vertex Pharmaceuticals Incorporated Common Stock (VRTX) i dag er 488,88 $, som gjenspeiler en bevegelse på −1,60 % siden markedet åpnet. Selskapets markedsverdi er $ 124,19 mrd., med et daglig handelsvolum på $ 496,47k aksjer. For investorer som følger kursutviklingen, har Vertex Pharmaceuticals Incorporated Common Stock-aksjen ligget mellom 484,40 $  og 498,03 $ i dag. Den forrige lukkekursen var 496,83 $.

Er du klar til å komme i gang? Følg trinnene nedenfor, eller les vår guide om hvordan kjøpe Vertex Pharmaceuticals aksje på Kraken fra $10.